Efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel for non‐small cell lung cancer patients who have failed at least two prior systemic treatments

BACKGROUND: The study was conducted to evaluate the efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel (NAB‐paclitaxel) treatment in patients with advanced non‐small‐cell lung cancer (NSCLC) who have undergone multi‐line therapy, and to investigate the association of sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Jianchun, Hao, Yueqin, Wan, Rui, Yu, Sifan, Bai, Hua, An, Tongtong, Zhao, Jun, Wang, Zhijie, Zhuo, Minglei, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415477/
https://www.ncbi.nlm.nih.gov/pubmed/28304139
http://dx.doi.org/10.1111/1759-7714.12413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415477/
https://www.ncbi.nlm.nih.gov/pubmed/28304139
http://dx.doi.org/10.1111/1759-7714.12413

Ejemplares similares